Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review-Reference-Cited by-同舟云学术

Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review

Published:2017-11 Issue:14 Volume:9 Page:1175-1183
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Abdel-Rahman Omar¹,Eltobgy Mostafa²,Oweira Hani³⁴⁵,Giryes Anwar³,Tekbas Aysun⁵,Decker Michael⁶

Affiliation:

1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 11566, Egypt

2. Faculty of Medicine, Ain Shams University, Cairo, Egypt

3. Oncology Department, Swiss Cancer Institute, Cham, Switzerland 3OncoCentrum Zurich, Gastrointestinal Tumor Center Zurich (GITZ), Zurich, Switzerland

4. Surgical Center Zurich – Hirslanden Hospital Zurich, Zurich, Switzerland

5. Surgery Department, University of Jena, Jena, Germany

6. Oncology Department, Zentrum für Integrative Onkologie, 8001 Zurich, Switzerland

Abstract

Aim: Immune-related musculoskeletal toxicities are uncommon but potentially serious adverse events; and they may accompany the use of immune checkpoint inhibitors (ICIs). The objective of this systematic review is to assess the patterns of these musculoskeletal toxicities. Methods & results: PubMed database has been searched till May 2017. Clinical studies and case reports reporting the occurrence of immune-related musculoskeletal toxicities (other than arthralgia and myalgia) in cancer patients treated with ICIs were included. Eight trials with 2263 participants were included. Likewise, nine case reports reporting the outcomes of 12 patients were included. Conclusion: Immune-related arthritis and myositis occur uncommonly in cancer patients treated with ICIs. Further studies are required to better describe the pathogenesis as well as the time course of these events.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2017-0108

Reference55 articles.

1. Cancer immunotherapy: moving beyond current vaccines

2. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

3. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

4. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors;Frontiers in Immunology;2023-10-06

2. Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis;Frontiers in Oncology;2023-09-29

3. Toxicities associated with immune checkpoint inhibitors: a systematic study;International Journal of Surgery;2023-05-03

4. Cross talks between autoimmunity and cancer;Translational Autoimmunity;2022

5. Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system;Immunotherapy;2021-12